7,107 Shares of AstraZeneca Plc $AZN Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of AstraZeneca Plc (NYSE:AZN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 7,107 shares of the company’s stock, valued at approximately $1,148,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in AZN. Profund Advisors LLC grew its position in AstraZeneca by 12.1% during the third quarter. Profund Advisors LLC now owns 3,921 shares of the company’s stock valued at $633,000 after buying an additional 422 shares during the period. Vise Technologies Inc. boosted its stake in shares of AstraZeneca by 2.9% during the 3rd quarter. Vise Technologies Inc. now owns 14,635 shares of the company’s stock worth $2,363,000 after acquiring an additional 416 shares during the last quarter. Summit Global Investments boosted its stake in shares of AstraZeneca by 5.2% during the 3rd quarter. Summit Global Investments now owns 6,884 shares of the company’s stock worth $1,112,000 after acquiring an additional 341 shares during the last quarter. Americana Partners LLC boosted its stake in shares of AstraZeneca by 5.1% during the 3rd quarter. Americana Partners LLC now owns 36,520 shares of the company’s stock worth $5,927,000 after acquiring an additional 1,781 shares during the last quarter. Finally, Aprio Wealth Management LLC grew its position in shares of AstraZeneca by 38.2% during the 3rd quarter. Aprio Wealth Management LLC now owns 4,870 shares of the company’s stock valued at $786,000 after acquiring an additional 1,346 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

AZN opened at $186.62 on Monday. The company has a 50 day simple moving average of $166.48 and a two-hundred day simple moving average of $180.22. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.01 and a quick ratio of 0.79. The firm has a market cap of $289.43 billion, a P/E ratio of 26.40, a PEG ratio of 1.45 and a beta of 0.24. AstraZeneca Plc has a 1-year low of $153.41 and a 1-year high of $212.71.

AstraZeneca (NYSE:AZN) last announced its quarterly earnings data on Friday, October 30th. The company reported $2.79 EPS for the quarter, beating the consensus estimate of $2.60 by $0.19. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The firm had revenue of $16.21 billion for the quarter, compared to the consensus estimate of $16 billion. During the same period last year, the firm earned $2.38 EPS. The company’s revenue was up 6.5% on a year-over-year basis. Equities analysts forecast that AstraZeneca Plc will post 10.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on AZN shares. Wall Street Zen upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. CICC Research began coverage on AstraZeneca in a report on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 target price on the stock. HSBC downgraded AstraZeneca from a “buy” rating to a “hold” rating in a research report on Monday, July 13th. Royal Bank Of Canada began coverage on AstraZeneca in a report on Tuesday, September 8th. They set an “outperform” rating for the company. Finally, Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, September 15th. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, AstraZeneca currently has an average rating of “Moderate Buy” and an average price target of $206.67.

About AstraZeneca

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.